natgillin/translations-raw huggingface dataset:
Den gennemsnitlige (% variationskoefficient) tenofovireksponering steg fra 2.185 (12 %) ng•t/ml hos probander med normal nyrefunktion til 3.064 (30 %) ng•t/ml, 6.009 (42 %) ng•t/ml og 15.985 (45 %) ng•t/ml hos patienter med henholdsvis let, moderat og svært nedsat nyrefunktion. 
The mean (%CV) tenofovir drug exposure increased from 2,185 (12%) ng•h/mL in patients with normal renal function, to 3,064 (30%) ng•h/mL, 6,009 (42%) ng•h/mL and 15,985 (45%) ng•h/mL, in patients with mild, moderate and severe renal impairment, respectively.
Ikke almindelig: rabdomyolyse3, 5, muskelsvaghed3, 5 Sjælden: 
rhabdomyolysis3, 5, muscular weakness3, 5
Ikke almindelig: pancreatitis3 
pancreatitis3
Lægemidler, der inducerer eller hæmmer CYP3A, kan derfor påvirke clearance af rilpivirin (se pkt. 
Rilpivirine is primarily metabolised by CYP3A Medicinal products that induce or inhibit CYP3A may thus affect the clearance of rilpivirine (see section 5.2).
Hvis De har hepatitis B, vil Deres læge nøje overveje den bedste behandling til Dem. To af de aktive stoffer i Eviplera (tenofovirdisoproxil og emtricitabin) viser nogen aktivitet mod hepatitis B-virus. 
Two of the active substances in Eviplera (tenofovir disoproxil and emtricitabine) show some activity against hepatitis B virus.
Rilpivirin er ikke blevet undersøgt hos patienter med svært nedsat leverfunktion (CPT score C) (se pkt. 
Rilpivirine has not been studied in patients with severe hepatic impairment (CPT Score C) (see section 4.2).
Hyppighed Bivirkning Blod- og lymfesystem Almindelig: 
Adverse reaction Blood and lymphatic system disorders
Eviplera er ikke blevet undersøgt hos patienter med svært nedsat leverfunktion (CPT score C). 
Eviplera has not been studied in patients with severe hepatic impairment (CPT Score C).
(kan opstå hos mere end 1 ud af 10 personer) 
(may affect more than 1 in 10 people)
Rilpivirins farmakokinetik er ikke undersøgt hos patienter med nedsat nyrefunktion. 
The pharmacokinetics of rilpivirine has not been studied in patients with renal insufficiency.
Prækliniske data for tenofovirdisoproxil viser ingen speciel risiko for mennesker vurderet ud fra konventionelle studier af sikkerhedsfarmakologi, genotoksicitet, karcinogenicitet samt reproduktions og udviklingstoksicitet. 
Non-clinical data on tenofovir disoproxil reveal no special hazard for humans based on conventional studies of safety pharmacology, genotoxicity, carcinogenic potential, and toxicity to reproduction and development.
Af disse virologiske svigt forekom 5/15 (rilpivirin) og 5/14 (efavirenz) hos patienter med en virusbelastning på ≤ 100.000 kopier/ml ved baseline. 
(rilpivirine) and 5/14 (efavirenz) were in patients with a baseline viral load of ≤ 100,000 copies/mL.
Emtricitabins farmakokinetik er ikke undersøgt hos patienter med nedsat leverfunktion. 
The pharmacokinetics of emtricitabine has not been studied in patients with hepatic impairment.
Metformin (850 mg enkeltdosis)/Rilpivirin Metformin: 
Metformin (850 mg single dose)/ Rilpivirine
Lopinavir (400 mg to gange dagligt)/Ritonavir (100 mg to gange dagligt)/Rilpivirin1 (blød kapsel) 
Lopinavir (400 mg twice daily)/ Ritonavir (100 mg twice daily)/ Rilpivirine1 (soft capsule)
Kombinationen af Eviplera og disse makrolidantibiotika kan forårsage en forhøjelse af plasmakoncentrationerne af rilpivirin (hæmmere af CYP3A-enzymer). 
The combination of Eviplera with these macrolide antibiotics may cause an increase in the plasma concentrations of rilpivirine (inhibition of CYP3A enzymes).
• Fedtlever 
• Fatty liver
(interaktionsmekanismen er ikke kendt) 
(mechanism of interaction unknown) Tenofovir:
Ethinylestradiol/Norethindron/Emtricitabin Interaktion er ikke undersøgt. 
Lopinavir/Ritonavir/Emtricitabine Interaction not studied.
Det er blevet observeret, at samtidig administration af Eviplera og protonpumpehæmmere nedsætter plasmakoncentrationer af rilpivirin (pga. en stigning i pH-værdien i ventriklen), hvilket kunne medføre tab af den terapeutiske virkning af Eviplera (se pkt. 
Co-administration of Eviplera with proton pump inhibitors has been observed to decrease the plasma concentrations of rilpivirine (due to an increase in gastric pH) which could potentially lead to loss of therapeutic effect of Eviplera (see section 4.3).
• Udslæt (inklusive røde pletter eller skjolder, undertiden med blærer eller hævelse af huden), som kan være allergiske reaktioner, kløe, ændringer i hudfarven, herunder pletvis mørkfarvning af huden 
• Rashes (including red spots or blotches sometimes with blistering and swelling of the skin),
(kan opstå hos op til 1 ud af 1.000 personer) 
(may affect up to 1 in 1,000 people)
Digoxin/Rilpivirin 
Digoxin/Rilpivirine
I de samlede data fra fase III-studierne C209 og C215 med behandlingsnaive patienter ved uge 96 var den gennemsnitlige ændring fra baseline i total-kolesterol (fastende) 5 mg/dl, i high-density lipoprotein (HDL)-kolesterol (fastende) 4 mg/dl, i low-density lipoprotein (LDL)-kolesterol (fastende) 1 mg/dl og i triglycerider (fastende) −7 mg/dl i rilpivirin-armen. 
At 96 weeks in the pooled Phase III C209 and C215 studies of treatment-naïve patients, in the rilpivirine arm the mean change from baseline in total cholesterol (fasted) was 5 mg/dL, in high-density lipoprotein (HDL)-cholesterol (fasted) 4 mg/dL, in low density lipoprotein (LDL)-cholesterol (fasted) 1 mg/dL, and in triglycerides (fasted) -7 mg/dL. At 48 weeks in Phase III study GS-US-264-0106 of virologically suppressed patients switching to Eviplera from a regimen containing a ritonavir-boosted PI, the mean change from baseline in total cholesterol (fasted) was -24 mg/dL, in HDL-cholesterol (fasted) -2 mg/dL, in LDL-cholesterol (fasted) -16 mg/dL, and in triglycerides (fasted) -64 mg/dL.
Andre antivirale midler Ledipasvir/sofosbuvir (90 mg/400 mg én gang dagligt)/Emtricitabin/rilpivirin/ tenofovirdisoproxil (200 mg/25 mg/245 mg én gang dagligt) 
Other antiviral agents Ledipasvir/Sofosbuvir (90 mg/400 mg once daily)/ Emtricitabine/Rilpivirine/ Tenofovir disoproxil (200 mg/25 mg/245 mg once daily)
• Emtricitabin, en nukleosid revers transkriptasehæmmer (NRTI). 
• Emtricitabine, a nucleoside reverse transcriptase inhibitor (NRTI).
Resistenstest for genotype og/eller historiske resistensdata skal være vejledende for anvendelsen af Eviplera (se pkt. 
Genotypic resistance testing and/or historical resistance data should guide the use of Eviplera (see sections 4.4 and 5.1).
Eviplera bør ikke anvendes sammen med systemisk dexamethason (undtagen som en enkeltdosis), da samtidig administration kan foråsage signifikant dosisafhængige reduktion i plasmakoncentrationen af rilpivirin (induktion af CYP3A-enzymer). 
Eviplera should not be used in combination with systemic dexamethasone (except as a single dose) as co-administration may cause significant dose dependent decreases in rilpivirine plasma concentrations (induction of CYP3A enzymes).
Norgestimat/Ethinylestradiol/ Tenofovirdisoproxil 
Norgestimate/Ethinylestradiol/ Tenofovir disoproxil
Samtidig infektion med Hepatitis B- og/eller hepatitis C-virus Generelt lignede emtricitabins farmakokinetik hos HBV-inficerede patienter den hos raske personer og hos hiv-inficerede patienter. 
In general, emtricitabine pharmacokinetics in HBV infected patients was similar to those in healthy subjects and in HIV infected patients.
4.4, 4.6, 5.1 og 5.2). 
Alternatively, switching to another antiretroviral regimen could be considered (see sections 4.4, 4.6, 5.1 and 5.2).
Hver filmovertrukken tablet indeholder 200 mg emtricitabin, 25 mg rilpivirin (som hydrochlorid) og 245 mg tenofovirdisoproxil (som fumarat). 
Each film-coated tablet contains 200 mg of emtricitabine, 25 mg of rilpivirine (as hydrochloride) and 245 mg of tenofovir disoproxil (as fumarate).
Eviplera indgives sammen med rifabutin, anbefales det at tage yderligere én rilpivirin-tablet på 25 mg dagligt samtidig med 
When Eviplera is co-administered with rifabutin, an additional 25 mg tablet of rilpivirine per day is recommended to be taken concomitantly with Eviplera, for the duration of the rifabutin coadministration.
Eviplera bør ikke indgives samtidig med adefovirdipivoxil (se pkt. 
Eviplera should not be administered concomitantly with adefovir dipivoxil (see section 4.5).
NATURLÆGEMIDLER Perikon (Hypericum perforatum) 
HERBAL PRODUCTS St. John's wort (Hypericum perforatum)
Det er usandsynligt, at en dosisjustering af Eviplera vil være nødvendig hos patienter med let eller moderat nedsat leverfunktion (se pkt. 
It is unlikely that a dose adjustment would be required for Eviplera in patients with mild or moderate hepatic impairment (see sections 4.2 and 5.2).
Kombinationen af Eviplera og H2-receptorantagonister skal anvendes med særlig forsigtighed, da samtidig anvendelse kan forårsage signifikant reduktion i plasmakoncentrationen af rilpivirin (reduceret absorption, forhøjelse af pHværdien i ventriklen). 
The combination of Eviplera and H2-receptor antagonists should be used with particular caution as co-administration may cause significant decreases in rilpivirine plasma concentrations (reduced absorption, increase in gastric pH).
Ethinylestradiol/Norethindron/ Tenofovirdisoproxil 
Ethinylestradiol/Norethindrone/ Tenofovir disoproxil
AUC: ↓ 10 % C12t: ↓ 13 % Cmax: ↓ 23 % 
AUC: ↓ 10% C12h: ↓ 13% Cmax: ↓ 23%
Tabel 5: Virologiske udfald af randomiseret behandling i studier C209 og C215 (samlede data for patienter, der får rilpivirinhydrochlorid eller efavirenz i kombination med emtricitabin/tenofovirdisoproxil) ved uge 48 (primært) og ved uge 96 
Table 5: Virologic outcomes of randomised treatment of studies C209 and C215 (pooled data for patients receiving rilpivirine hydrochloride or efavirenz in combination with emtricitabine/tenofovir disoproxil) at week 48 (primary) and week 96
Hver Eviplera filmovertrukket tablet indeholder 200 mg emtricitabin, 25 mg rilpivirin (som hydrochlorid) og 245 mg tenofovirdisoproxil (som fumarat). 
Each Eviplera film-coated tablet contains 200 mg of emtricitabine, 25 mg of rilpivirine (as hydrochloride) and 245 mg of tenofovir disoproxil (as fumarate).
Simeprevir (150 mg en gang dagligt)/rilpivirin (25 mg en gang dagligt) 
Simeprevir (150 mg once daily)/ Rilpivirine (25 mg once daily)
5.1) indikerer, at den korte periode med lavere rilpivirin-eksponering ikke påvirker Evipleras antivirale virkning. 
The efficacy data from study GS-US-264-0111 (see section 5.1) indicates that the brief period of lower rilpivirine exposure does not impact antiviral efficacy of Eviplera.
ANTIARYTMIKA Digoxin/Emtricitabin 
ANTIARRHYTHMICS Digoxin/Emtricitabine
manglende virkning eller tab af virkning, patienter, som seponerede af andre årsager end bivirkninger (AE) eller død, og som på seponeringstidspunktet havde en virusbelastning ≥ 50 kopier/ml. 
c Includes patients who had HIV-1 RNA ≥ 50 copies/mL in the week 24 window, patients who discontinued early due to lack or loss of efficacy, patients who discontinued for reasons other than an adverse event (AE) or death, and at the time of discontinuation had a viral value of ≥ 50 copies/mL.
Paracetamol (500 mg enkeltdosis)/Rilpivirin1 Paracetamol: 
Paracetamol (500 mg single dose)/ Rilpivirine1
Sofosbuvir/ tenofovirdisoproxil 
Sofosbuvir/Tenofovir disoproxil
Tabel 4: Demografiske og baselinekarakteristika af hiv 1-inficerede voksne patienter, som er naive med hensyn til antiretroviral behandling, og stadig er i studierne C209 og C215 (samlede data for patienter, der fik rilpivirinhydrochlorid eller efavirenz i kombination med emtricitabin/tenofovirdisoproxil) ved uge 96 
Table 4: Demographic and baseline characteristics of antiretroviral treatment-naïve HIV-1 infected adult patients in studies C209 and C215 (pooled data for patients receiving rilpivirine hydrochloride or efavirenz in combination with emtricitabine/tenofovir disoproxil) at week 96
Rifabutin kan nedsætte mængden af rilpivirin (et aktivt stof i Eviplera) i Deres blod. 
This medicine can decrease the amount of rilpivirine (a component of Eviplera) in your blood.
• Problemer med bugspytkirtlen 
• Pancreas problems
Rifampicin (600 mg én gang dagligt)/ Rilpivirin1 
Rifampicin (600 mg once daily)/ Rilpivirine1
• Døsighed 
• Drowsiness
Eviplera må ikke anvendes sammen med præparater, der indeholder perikon, da samtidig administration kan forårsage signifikant reduktion i plasmakoncentrationen af rilpivirin. 
Eviplera must not be used in combination with products containing St. John's wort as coadministration may cause significant decreases in rilpivirine plasma concentrations.
Efavirenz + emtricitabin/ tenofovirdisoproxil n = 550 
Rilpivirine + Emtricitabine/Tenofovir disoproxil n = 550
Atorvastatin (40 mg én gang dagligt)/ Rilpivirin1 
Atorvastatin (40 mg once daily)/ Rilpivirine1
Da Eviplera kan foråsage nyreskader, anbefales monitorering af nyrefunktionen (se pkt. 
As Eviplera may cause renal damage, monitoring of renal function is recommended (see sections 4.4 and 4.8, Summary of the safety profile).
Kombinationen af Eviplera og antacida bør anvendes med forsigtighed, da samtidig administration kan forårsage signifikant reduktion i plasmakoncentrationen af rilpivirin (reduceret absorption, forhøjelse af pHværdien i ventriklen). 
The combination of Eviplera and antacids should be used with caution as co-administration may cause significant decreases in rilpivirine plasma concentrations (reduced absorption, gastric pH increase).
Rifampicin (600 mg én gang dagligt)/ Tenofovirdisoproxil (245 mg én gang dagligt) 
Rifampicin (600 mg once daily)/ Tenofovir disoproxil (245 mg once daily)
Når supraterapeutiske doser af rilpivirinhydrochlorid på 75 mg én gang dagligt og 300 mg én gang dagligt blev undersøgt hos raske voksne, var de maksimale gennemsnitstids-matchede (95 % øvre konfidensinterval) forskelle i QTcF-intervallet fra placebo efter baselinekorrektion hhv. 10,7 (15,3) og 23,3 (28,4) ms. Steady-state administration af rilpivirinhydrochlorid 75 mg én gang dagligt og 300 mg én gang dagligt resulterede i en gennemsnitlig Cmax hhv. ca. 2,6 gange og 6,7 gange højere end den gennemsnitlige steady-state Cmax, der blev observeret med den anbefalede dosis på rilpivirinhydrochlorid på 25 mg én gang dagligt. 
When supratherapeutic doses of 75 mg once daily and 300 mg once daily of rilpivirine hydrochloride were studied in healthy adults, the maximum mean time-matched (95% upper confidence bound) differences in QTcF interval from placebo after baseline correction were 10.7 (15.3) and 23.3 (28.4) ms, respectively.
Ketoconazol (400 mg én gang dagligt)/ Rilpivirin1 
Ketoconazole (400 mg once daily)/ Rilpivirine1
Sofosbuvir/velpatasvir (400 mg/100 mg én gang dagligt)/ Emtricitabin/rilpivirin/tenofovirdisoproxil (200 mg/25 mg/245 mg én gang dagligt) 
Sofosbuvir/Velpatasvir (400 mg/100 mg once daily)/ Emtricitabine/Rilpivirine/Tenofovir disoproxil (200 mg/25 mg/245 mg once daily)
Tenofovirs tilsyneladende clearance var i gennemsnit ca. 
The apparent clearance of tenofovir averaged approximately 307 mL/min.
Ætiologien anses dog for at være multifaktoriel (omfattende anvendelse af binyrebarkhormoner alkoholforbrug, svær immunosuppression, højere Body Mass Index (BMI)). 
Although the aetiology is considered to be multifactorial (including corticosteroid use, alcohol consumption, severe immunosuppression, higher body mass index), cases of osteonecrosis have been reported particularly in patients with advanced HIV disease and/or long-term exposure to CART.
Simeprevir (150 mg en gang dagligt)/ Tenofovirdisoproxil (245 mg en gang dagligt) 
Simeprevir (150 mg once daily)/ Tenofovir disoproxil (245 mg once daily)
Tabel 6: Data for fænotype-resistens fra studierne C209 og C215 (samlede data for patienter, der får rilpivirinhydrochlorid eller efavirenz i kombination med emtricitabin/tenofovirdisoproxil) ved uge 96 (baseret på resistensanalyse) 
Table 6: Phenotypic resistance outcomes from studies C209 and C215 (pooled data for patients receiving rilpivirine hydrochloride or efavirenz in combination with emtricitabine/tenofovir disoproxil) at week 96 (based on resistance analysis)
Sofosbuvir (400 mg én gang dagligt)/rilpivirin (25 mg én gang dagligt) 
Sofosbuvir (400 mg once daily)/ Rilpivirine (25 mg once daily)
Sildenafil/Tenofovirdisoproxil 
Sildenafil/Tenofovir disoproxil
Paracetamol/Tenofovirdisoproxil 
Paracetamol/Tenofovir disoproxil
Rifabutin (300 mg én gang dagligt)/Rilpivirin3 Rifabutin: 
Rifabutin (300 mg once daily)/ Rilpivirine3
Patienter med moderat eller svært nedsat nyrefunktion kræver justering af doseringsintervallet for emtricitabin og tenofovirdisoproxil, der ikke kan opnås med kombinationstabletten (se pkt. 
Patients with moderate or severe renal impairment require a dose interval adjustment of emtricitabine and tenofovir disoproxil that cannot be achieved with the combination tablet (see sections 4.2 and 5.2).
Famotidin (40 mg enkeltdosis, der tages 12 timer før rilpivirin)/Rilpivirin1 
Famotidine (40 mg single dose taken 12 hours before rilpivirine)/ Rilpivirine1
neutropeni1, nedsat leukocyttal2, nedsat hæmoglobin2, nedsat trombocyttal2 Ikke almindelig: anæmi1, 4 
neutropenia1, decreased white blood cell count2, decreased haemoglobin2, decreased platelet count2
• Hvis De aktuelt tager nogle af de følgende former for medicin • carbamazepin, oxcarbazepin, phenobarbital og phenytoin (medicin til behandling af epilepsi og til at forebygge krampeanfald) 
• carbamazepine, oxcarbazepine, phenobarbital and phenytoin (medicines to treat epilepsy and prevent seizures) • rifampicin and rifapentine (used to treat some bacterial infections such as tuberculosis)
Atazanavir (300 mg én gang dagligt)/Ritonavir (100 mg én gang dagligt)/Tenofovirdisoproxil (245 mg én gang dagligt) 
Atazanavir (300 mg once daily)/ Ritonavir (100 mg once daily)/ Tenofovir disoproxil (245 mg once daily)
Patienter med moderat eller svært nedsat nyrefunktion kræver en justering af dosisintervallet af emtricitabin og tenofovirdisoproxil, der ikke kan opnås med kombinationstabletten (se pkt. 
Patients with moderate or severe renal impairment require a dose interval adjustment of emtricitabine and tenofovir disoproxil that cannot be achieved with the combination tablet (see sections 4.4 and 5.2).
Darunavir (300 mg én gang dagligt)/Ritonavir (100 mg én gang dagligt)/Tenofovirdisoproxil (245 mg én gang dagligt) 
Darunavir (300 mg once daily)/ Ritonavir (100 mg once daily)/ Tenofovir disoproxil (245 mg once daily)
Sådan skal De tage Eviplera 
How to take Eviplera
Seponering af behandlingen med Eviplera hos hiv-inficerede patienter, der samtidig er inficeret med HBV, kan forekomme i forbindelse med svær, akut eksacerbation af hepatitis (se pkt. 
Discontinuation of Eviplera therapy in patients co-infected with HIV and HBV may be associated with severe acute exacerbations of hepatitis (see section 4.4).
b Forskellen i responsrate er 1 % (95 % konfidensinterval −3 % til 6 %) ved brug af normalapproksimation. 
Discontinued for non-AE reasone n = total number of patients per treatment group a ITT TLOVR = Intention to treat time to loss of virologic response b The difference of response rate is 1% (95% confidence interval -3% to 6%) using normal approximation.
Maraviroc (300 mg to gange dagligt)/ Tenofovirdisoproxil (245 mg én gang dagligt) 
Maraviroc (300 mg twice daily)/ Tenofovir disoproxil (245 mg once daily)
Eviplera må ikke anvendes sammen med disse antikonvulsiva, da samtidig administration kan forårsage signifikant reduktion i plasmakoncentrationen af rilpivirin (induktion af CYP3A-enzymer). 
Eviplera must not be used in combination with these anticonvulsants as co-administration may cause significant decreases in rilpivirine plasma concentrations (induction of CYP3A enzymes).
Famotidin (40 mg enkeltdosis, der tages 4 timer efter rilpivirin)/Rilpivirin1 
Famotidine (40 mg single dose taken 4 hours after rilpivirine)/ Rilpivirine1
Omeprazol (20 mg én gang dagligt)/Rilpivirin1 Omeprazol: 
Omeprazole (20 mg once daily)/ Rilpivirine1
Rifabutin (300 mg én gang dagligt)/Rilpivirin (50 mg én gang dagligt) 
Rifabutin (300 mg once daily)/ Rilpivirine (50 mg once daily)
Eviplera må ikke anvendes sammen med protonpumpehæmmere, da samtidig administration, sandsynligvis forårsage signifikant reduktion i plasmakoncentrationen af rilpivirin (reduceret absorption, forhøjelse af pH-værdien i ventriklen). 
Eviplera must not be used in combination with proton pump inhibitors as co-administration is likely to cause significant decreases in rilpivirine plasma concentrations (reduced absorption, increase in gastric pH).
Famotidin (40 mg enkeltdosis, der tages 2 timer før rilpivirin)/Rilpivirin1 
Famotidine (40 mg single dose taken 2 hours before rilpivirine)/ Rilpivirine1
Cmin: ↔* Cmax: ↑ 43 %* 
AUC: ↑ 16%* Cmin: ↔* Cmax: ↑ 43%*
Ribavirin/ tenofovirdisoproxil 
Ribavirin/Tenofovir disoproxil
PROTONPUMPEHÆMMERE Omeprazol/Emtricitabin 
PROTON PUMP INHIBITORS Omeprazole/Emtricitabine
Rifabutin/Tenofovirdisoproxil 
Rifabutin/Tenofovir disoproxil
Tabel 3: Data for fænotype-resistens og krydsresistens fra studier C209 and C215 (samlede data) ved uge 96 for patienter, der fik rilpivirinhydrochlorid i kombination med emtricitabin/tenofovirdisoproxil (baseret på resistensanalyse) 
Table 3: Phenotypic resistance and cross-resistance outcomes from studies C209 and C215 (pooled data) for patients receiving rilpivirine hydrochloride in combination with emtricitabine/tenofovir disoproxil at week 96 (based on resistance analysis)
Cmin: N/A Tenofovir: AUC: ↔ 
Cmin: N/A Tenofovir:
• Svaghedsfølelse 
• Feeling weak
Digoxin/Tenofovirdisoproxil 
Digoxin/Tenofovir disoproxil
Eviplera må ikke anvendes sammen med rifapentin, da samtidig administration sandsynligvis kan forårsage signifikant reduktion i plasmakoncentrationen af rilpivirin (induktion af CYP3A-enzymer). 
Eviplera must not be used in combination with rifapentine as co-administration is likely to cause significant decreases in rilpivirine plasma concentrations (induction of CYP3A enzymes).
Metformin/Tenofovirdisoproxil 
Metformin/Tenofovir disoproxil
Atorvastatin/Tenofovirdisoproxil 
Atorvastatin/Tenofovir disoproxil
Rifabutin (300 mg én gang dagligt)/Rilpivirin (25 mg én gang dagligt) 
Rifabutin (300 mg once daily)/ Rilpivirine (25 mg once daily)
• Hvis De kommer i tanker om det inden for 12 timer efter det tidspunkt, De normalt tager 
• If you notice within 12 hours of the time you usually take Eviplera, you must take the tablet as soon as possible.
En streng doseringsplan med en indtagelse af H2receptorantagonister mindst 
A strict dosing schedule with intake of the H2-receptor antagonists at least 12 hours before or at least 4 hours after Eviplera should be used.
Lopinavir (400 mg to gange dagligt)/Ritonavir (100 mg to gange dagligt)/Tenofovirdisoproxil (245 mg én gang dagligt) 
Lopinavir (400 mg twice daily)/ Ritonavir (100 mg twice daily)/ Tenofovir disoproxil (245 mg once daily)
Omeprazol/Tenofovirdisoproxil 
Omeprazole/Tenofovir disoproxil
Methadon/Tenofovirdisoproxil 
Methadone/Tenofovir disoproxil
• Diarré, opkastning, kvalme 
• Diarrhoea, being sick (vomiting), feeling sick (nausea)
(protonpumpehæmmere, der er medicin til forebyggelse og behandling af mavesår, halsbrand, sure opstød (reflukssygdom)) 
• omeprazole, lansoprazole, rabeprazole, pantoprazole and esomeprazole (proton pump inhibitors that are medicines used to prevent and treat stomach ulcers, heartburn, acid reflux disease)
Derfor frarådes Eviplera hos patienter med svært nedsat leverfunktion (se pkt. 
Therefore, Eviplera is not recommended in patients with severe hepatic impairment (see sections 4.4 and 5.2).
hovedpine1, 2, 3, svimmelhed1, 2, 3 
Very common: headache1, 2, 3, dizziness1, 2, 3 Common:
Eviplera indeholder et farvestof, der kaldes Sunset yellow FCF aluminium lak (E110). 
Eviplera contains a colourant called sunset yellow aluminium lake (E110), which may cause allergic reactions.
Norethindron (1 mg én gang dagligt)/Rilpivirin Norethindron: 
Norethindrone (1 mg once daily)/ Rilpivirine
Indigocarmin aluminiumpigment Lactosemonohydrat 
Indigo carmine aluminium lake Lactose monohydrate Polyethylene glycol Red iron oxide
Famotidin/Tenofovirdisoproxil 
Famotidine/Tenofovir disoproxil
Virologisk succes efter 24 ugers behandlingb hiv 1-rna < 50 kopier/ml 
Virologic success after 24 weeks of treatmentb
Cmax: ↓ 15 % Cmin: ↓ 7 % 
AUC: ↓ 14% Cmax: ↓ 15% Cmin: ↓ 7%